ライフサイエンスコーパス: simvastatin

1 wo other hydrophobic statins, lovastatin and simvastatin.

2 ezetimibe/simvastatin (E/S) or 40 mg placebo/simvastatin.

3 eatment with the HMG-CoA reductase inhibitor simvastatin.

4 ed with sepsis was assessed with and without simvastatin.

5 coronary syndrome (ACS) compared to placebo/simvastatin.

6 ular protection of calpastatin induction and simvastatin.

7 CR3 ligand-binding I domain in complex with simvastatin.

8 ein in vitro, and this could be prevented by simvastatin.

9 oronary syndrome to simvastatin or ezetimibe/simvastatin.

10 nofibrate plus simvastatin with placebo plus simvastatin.

11 reporting ratio and reporting odds ratio for simvastatin.

12 h SPMS were randomized to receive placebo or simvastatin.

13 atients using atorvastatin, pravastatin, and simvastatin.

14 , lovastatin, pravastatin, rosuvastatin, and simvastatin.

15 Of note, administration of simvastatin (0.2 mg/kg) did not significantly up-regulat

16 41-0.64), pravastatin (0.40; 0.28-0.58), and simvastatin (0.33; 0.21-0.52) were all significantly ass

17 e to receive a polypill (containing 40 mg of simvastatin, 100 mg of atenolol, 25 mg of hydrochlorothi

18 atin and rosuvastatin at doses equivalent to simvastatin 20 mg daily reduced the odds of MACEs in thi

19 Participants were randomly assigned to simvastatin 20 mg tablets twice-daily plus vitamin D3 1,

20 We recommend simvastatin 20 mg/day as the dose to be used in studies

21 40 mg/day plus rifaximin 1200 mg/day (n=18), simvastatin 20 mg/day plus rifaximin 1200 mg/day (n=16),

22 statin 40 mg/day plus rifaximin 1200 mg/day, simvastatin 20 mg/day plus rifaximin 1200 mg/day, or pla

23 ences at 12 weeks in AST and ALT between the simvastatin 20 mg/day plus rifaximin and placebo group (

24 ignificant changes in creatine kinase in the simvastatin 20 mg/day plus rifaximin group (4.2 IU/L [-8

25 simvastatin 40 mg/day plus rifaximin or the simvastatin 20 mg/day plus rifaximin groups compared wit

26 plus rifaximin 1200 mg/day group, 14 in the simvastatin 20 mg/day plus rifaximin mg/day group, and 1

27 , particularly rhabdomyolysis, compared with simvastatin 20 mg/day plus rifaximin.

28 d-Pugh class of A or B vs C, to groups given simvastatin (20 mg/d the first 15 days, 40 mg/d thereaft

29 nts were randomly assigned to receive either simvastatin 40 mg (n=391) or placebo (n=412).

30 Simvastatin 40 mg and atorvastatin 40 mg accounted for 2

31 years of randomized treatment with combined simvastatin 40 mg and ezetimibe 10 mg daily or placebo.

32 We aimed to determine whether simvastatin 40 mg could improve the long-term outcome in

33 e randomly allocated (1:1) to receive either simvastatin 40 mg or placebo once a day for up to 21 day

34 Three (19%) patients in the simvastatin 40 mg/day group developed liver and muscle t

35 50 patients were randomly assigned to simvastatin 40 mg/day plus rifaximin 1200 mg/day (n=18),

36 analysis set included 44 patients (16 in the simvastatin 40 mg/day plus rifaximin 1200 mg/day group,

37 assigned patients (1:1:1) to receive either simvastatin 40 mg/day plus rifaximin 1200 mg/day, simvas

38 verse events was significantly higher in the simvastatin 40 mg/day plus rifaximin group (nine [56%] o

39 nt, treatment was stopped prematurely in the simvastatin 40 mg/day plus rifaximin group due to recomm

40 Patients in the simvastatin 40 mg/day plus rifaximin group showed a sign

41 Patients in the simvastatin 40 mg/day plus rifaximin group showed an inc

42 Treatment with simvastatin 40 mg/day plus rifaximin in patients with de

43 nces in alkaline phosphatase between the the simvastatin 40 mg/day plus rifaximin or the simvastatin

44 rvastatin 20-<40 mg, rosuvastatin 10-<20 mg, simvastatin 40-<80 mg), and 12.9% low-dose statins (ator

45 The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-e

46 g) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy

47 y, moderate-intensity (atorvastatin [10 mg], simvastatin [40 mg], or rosuvastatin [5 mg]) or high-int

48 s were randomly assigned to receive 80 mg of simvastatin (42 donors) via nasogastric tube after decla

49 eptance as a cardiac donor, or to receive no simvastatin (42 donors).

50 igned patients (1:1 ratio) to receive either simvastatin 80 mg or placebo daily for up to a maximum o

51 ble-blind, placebo-controlled pilot study of simvastatin 80 mg or placebo for 7 days for patients wit

52 torvastatin 40-80 mg, rosuvastatin 20-40 mg, simvastatin 80 mg), 28.6% moderate-dose statins (atorvas

53 n 40 to 80 mg, rosuvastatin 20 to 40 mg, and simvastatin 80 mg.

54 nth were more likely randomized to ezetimibe/simvastatin (85%), had lower baseline LDL-C values, and

55 xposed to TCDD in the presence or absence of simvastatin, a competitive inhibitor of HMGCR.

56 .Measurements and Main Results: Four days of simvastatin adjuvant therapy in patients with CAP + S wa

57 Experimental studies show that simvastatin administered to the organ donor is vasculopr

58 tin met dual targets than those treated with simvastatin alone (50% versus 29%, P<0.001).

59 ed in greater LDL-C reductions compared with simvastatin alone at 33 weeks (mean, -54.0% [SD, 1.4%] v

60 nd a study of simvastatin + ezetimibe versus simvastatin alone in 6-month cardiovascular outcomes.

61 MPROVE-IT (ezetimibe plus simvastatin versus simvastatin alone in individuals with cardiovascular dis

62 apy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant redu

63 nd hs-CRP targets than patients treated with simvastatin alone.

64 Simvastatin, an agent for hypercholesterolemia treatment

65 The present study demonstrates that simvastatin, an antihyperlipidemic drug exhibited broad-

66 a signaling and recent studies revealed that simvastatin, an FDA-approved cholesterol-lowering medica

67 Simvastatin, an HMG-coA reductase inhibitor, is known to

68 ber of ventilator-free days (12.6+/-9.9 with simvastatin and 11.5+/-10.4 with placebo, P=0.21) or day

69 tween the two groups (5.7 days [SD 5.1] with simvastatin and 6.1 days [5.2] with placebo; mean differ

70 stronger effects by fluvastatin, followed by simvastatin and atorvastatin, and with a limited effect

71 ed LDL-C and hs-CRP targets and outcomes for simvastatin and ezetimibe/simvastatin was prespecified i

72 being the most effective, while statins like simvastatin and fluvastatin having lower effectiveness.

73 Our findings identify a novel activity of simvastatin and mechanism of SASP regulation.

74 Antioxidants such as simvastatin and N-acetyl cysteine improved arterial dysf

75 erbations per person-year was similar in the simvastatin and placebo groups: 1.36+/-1.61 exacerbation

76 ided net benefit at lower 10-year risks than simvastatin and pravastatin.

77 65 self-reported white subjects treated with simvastatin and randomized to fenofibrate or placebo in

78 Using simvastatin and sham incubated lymphoblastoid cell lines

79 lipid composition were similar for high-dose simvastatin and simvastatin/ezetimibe combination therap

80 Simvastatin and TCDD (S + T) co-treatment increased hepa

81 ere exposed to lovastatin, atorvastatin, and simvastatin and the minimum inhibitory concentrations (M

82 eatment with the HMG-CoA reductase inhibitor simvastatin, and 3) shRNA-mediated knockdown of SREBP2.

83 The mice then were treated with or without simvastatin, and the spleen was harvested to measure the

84 ligand binding kinetics as discriminator for simvastatin antagonism.

85 Simvastatin antagonizes I domain binding to the compleme

86 Simvastatin appears to be a promising therapeutic strate

87 in the placebo+simvastatin versus ezetimibe+simvastatin arm (KM rate 52.0% versus 49.8%, P=0.049) an

88 Repurposing simvastatin as a therapy for preterm labor: evidence fro

89 ion for further investigation of repurposing simvastatin as a topical antibacterial agent to treat sk

90 lusions: This pilot study supports high-dose simvastatin as an adjuvant therapy for CAP + S in an old

91 ions, while enabling assessment of potential simvastatin-associated pleiotropic effects.

92 Simvastatin-associated reports showed signals for higher

93 Simvastatin at a daily dose of 40 mg did not affect exac

94 hin the previous 48 hours to receive enteral simvastatin at a dose of 80 mg or placebo once daily for

95 Simvastatin, being highly effective against P. gingivali

96 beta-methylcyclodextrin) or statin compound (simvastatin) blocked ATP and IL-33 release by lowering t

97 We found that simvastatin both prevented and reversed depigmentation i

98 We confirmed that simvastatin caused the translocation of the small Rho GT

99 f the Cholesterol and Pharmacogenetics (CAP) simvastatin clinical trial, we found that statin-induced

100 ro and in vivo experiments demonstrated that simvastatin combined with tamoxifen increased TamR cell

101 erol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associat

102 ective of this study is to determine whether simvastatin consumption and hyperlipidemia are associate

103 rations of CDK4/6 and Cyclin D1 triggered by simvastatin could be recovered by PPARgamma-antagonist (

104 Simvastatin decreased burn-induced TNF-alpha and NF-kapp

105 The lipid-lowering drug simvastatin decreases portal pressure, improves hepatoce

106 Here, we show that simvastatin decreases the SASP of senescent human fibrob

107 In contrast, simvastatin did not change Rho-GTP loading in A549 and M

108 Simvastatin did not further decrease burn-caused apoptos

109 Simvastatin did not increase survival of patients with C

110 We observed simvastatin did not trigger BCa cell apoptosis, but redu

111 production, suggesting additional effects of simvastatin directly on T cells.

112 the magnitude of the reduction was linked to simvastatin dosage.

113 igher simvastatin doses (by 0.44 mm(2)/10 mg simvastatin dose equivalent; P = .02).

114 .01 mm(2); P = .03) and in those with higher simvastatin doses (by 0.44 mm(2)/10 mg simvastatin dose

115 Simvastatin dramatically reduced damage and enhanced mus

116 2) with ezetimibe/simvastatin versus placebo/simvastatin, driven by a significant 21% reduction in is

117 orrhage should not be treated routinely with simvastatin during the acute stages.

118 125 mg/dL were randomized to 40 mg ezetimibe/simvastatin (E/S) or 40 mg placebo/simvastatin.

119 Here, we aimed to explore whether simvastatin effects on brain atrophy and disability in s

120 ld mdx mice with severe muscle degeneration, simvastatin enhanced diaphragm force and halved fibrosis

121 Furthermore, the simvastatin-evoked reduction of VDAC-1 expression in the

122 Additionally, simvastatin exhibits excellent anti-biofilm activity aga

123 Simvastatin exposure decreased TCDD-induced hepatic lipi

124 tomatic aortic stenosis participating in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study.

125 We used data from the SEAS trial (Simvastatin Ezetimibe in Aortic Stenosis) to assess what

126 th gastrointestinal bleeding, and a study of simvastatin + ezetimibe versus simvastatin alone in 6-mo

127 rimary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in t

128 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg pe

129 nternational Trial) to examine the impact of simvastatin-ezetimibe versus simvastatin-placebo on card

130 f simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40

131 n were similar for high-dose simvastatin and simvastatin/ezetimibe combination therapy, but the magni

132 Simvastatin, fluvastatin, and pravastatin showed the mos

133 n vivo, we treated Parkin knockout mice with simvastatin for 2 wk.

134 Pretreatment with simvastatin for 24 h also inhibited the increase in tigh

135 ontaining aspirin, lisinopril, atenolol, and simvastatin for secondary prevention of atherosclerotic

136 the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke and other adver

137 e was significantly lower in patients in the simvastatin group (0.288% per year [SD 0.521]) than in t

138 lacebo group died (22%) vs 6 patients in the simvastatin group (9%) (hazard ratio for adding simvasta

139 nts in the placebo group and 22 of 69 in the simvastatin group (P = .423).

140 patients in the placebo group and 25% in the simvastatin group (P = .583).

141 11% in the placebo group vs 8% in the in the simvastatin group (P = .599).

142 patients in the placebo group and 49% in the simvastatin group (P = .752); the percentages of serious

143 The simvastatin group also had a 2.5 points better mean phys

144 in the placebo group and no patients in the simvastatin group although this difference was not stati

145 6 months, we recorded 37 (10%) deaths in the simvastatin group compared with 35 (9%) in the placebo g

146 serious adverse events were reported in the simvastatin group compared with 74 (18%) in the placebo

147 urable outcome, mRS 0-2 (271 patients in the simvastatin group vs 289 in the placebo group).

148 he upper limit of normal (eight [11%] in the simvastatin group vs three [4%] in the placebo group p=0

149 Two patients in the simvastatin group, each with advanced liver disease, dev

150 diated by brain atrophy, and direct effects, simvastatin had a direct effect (independent of serum ch

151 Simvastatin had a similar effect, but the combination of

152 Importantly, simvastatin has also been reported to have anti-tumor ef

153 m in the pathogenesis of delirium, and since simvastatin has anti-inflammatory properties it might re

154 Simvastatin has been shown to possess potent anti-inflam

155 eatment with atorvastatin or rosuvastatin or simvastatin, hepatitis C virus infection, prior treatmen

156 rial of ezetimibe/simvastatin versus placebo/simvastatin (IMPROVE-IT [Improved Reduction of Outcomes:

157 Lipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes.

158 nfirming in vitro results, high-dose (80-mg) simvastatin improved neutrophil migratory accuracy witho

159 Moreover, simvastatin improved restenosis indicators by suppressin

160 doses.Objectives: To determine if high-dose simvastatin improves neutrophil functions and is safe an

161 ezetimibe and simvastatin or to placebo and simvastatin in IMPROVE-IT (Improved Reduction of Outcome

162 poprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction of Outcome

163 The use of ezetimibe/simvastatin versus simvastatin in IMPROVE-IT (Improved Reduction of Outcome

164 to receive ezetimibe/simvastatin or placebo/simvastatin in IMPROVE-IT.

165 tified a p53(R270H) -specific sensitivity to simvastatin in lung tumors, and the transcriptional sign

166 aluated placebo+simvastatin versus ezetimibe+simvastatin in patients hospitalized with the acute coro

167 The addition of ezetimibe to simvastatin in patients stabilized after acute coronary

168 ssessed the safety of two different doses of simvastatin, in combination with rifaximin, in patients

169 by 9% with ezetimibe/simvastatin vs placebo/simvastatin (incidence-rate ratio [RR]: 0.91; 95% confid

170 Simvastatin induced apoptotic cell death via the intrins

171 over, flow cytometry analysis indicated that simvastatin induced cell cycle arrest at G0/G1 phase, su

172 Here we show that the MEV cascade inhibitor simvastatin induced significant cell death in a wide ran

173 ults indicate that MEV cascade inhibition by simvastatin induced the intrinsic apoptosis pathway via

174 protective agents, including fenofibrate and simvastatin, induced NEAT1 up-regulation, whereas RNA in

175 In all cancer cell types tested, simvastatin-induced cell death was not rescued by choles

176 plicated in adverse drug reactions including simvastatin-induced myopathy and docetaxel-induced neutr

177 Simvastatin-induced Rho-GTP loading significantly increa

178 l cells and that vimentin overexpression and simvastatin-induced vimentin bundling inhibit fast amoeb

179 Here we demonstrate that simvastatin induces mitophagy in skeletal muscle cells a

180 Simvastatin inhibited 3-hydroxy-3-methyl-glutaryl-CoA re

181 , our study for the first time revealed that simvastatin inhibited bladder cancer cell proliferation

182 Critically, simvastatin inhibited myometrial cell contraction, basal

183 In addition, simvastatin inhibited the increase in tight junction mac

184 romolecular synthesis analyses revealed that simvastatin inhibits multiple biosynthetic pathways and

185 Here we show that simvastatin inhibits the proliferation of human leiomyom

186 ipoprotein cholesterol compared with placebo/simvastatin, irrespective of DM (DM: 49 versus 67 mg/dL;

187 udy, the findings suggest that the intake of simvastatin is associated with increasing serum OPG conc

188 Simvastatin is currently one of the most common drugs fo

189 ibitors, allopurinol, mometasone, metformin, simvastatin, levothyroxine were inversely associated.

190 s (atorvastatin <20 mg, rosuvastatin <10 mg, simvastatin <40 mg).

191 Based on these data, simvastatin may be a safe, targeted treatment option for

192 Therefore, we hypothesized that simvastatin may be an effective treatment for vitiligo.

193 In conclusion, simvastatin may suppress TamR cell growth by inhibiting

194 More patients treated with ezetimibe/simvastatin met dual targets than those treated with sim

195 icantly more patients treated with ezetimibe/simvastatin met prespecified and exploratory dual LDL-C

196 docrine resistance in breast cancer and that simvastatin might suppress this resistance.

197 We also show that simvastatin mitigates the effects of senescent condition

198 Simvastatin modified surface adhesion molecule expressio

199 e results do not support the hypothesis that simvastatin modifies duration of delirium and coma in cr

200 mpared with simvastatin (40 mg) and placebo (simvastatin monotherapy).

201 etimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference,

202 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001).

203 nine patients were treated with either 80 mg simvastatin (n=20) or 10 mg simvastatin plus 10 mg ezeti

204 were randomly assigned (1:1) to either 80 mg simvastatin (n=70) or placebo (n=70).

205 2 patients were randomly assigned to receive simvastatin (n=71) or placebo (n=71), and were included

206 We found evidence of a positive effect of simvastatin on frontal lobe function and a physical qual

207 Although we found no effect of simvastatin on the other outcome measures, these potenti

208 t a protective effect of statins--especially simvastatin--on breast cancer recurrence.

209 ronary syndrome were randomized to a placebo/simvastatin or ezetimibe/simvastatin regimen and followe

210 stabilized after acute coronary syndrome to simvastatin or ezetimibe/simvastatin.

211 in patients randomized to receive ezetimibe/simvastatin or placebo/simvastatin in IMPROVE-IT.

212 Finally, oral administration of simvastatin or the antioxidant apocynin reduced aneurysm

213 ng the cholesterol content of HBE cells with simvastatin or the cholesterol scavenger beta-methylcycl

214 patients randomized either to ezetimibe and simvastatin or to placebo and simvastatin in IMPROVE-IT

215 no benefit with the addition of ezetimibe to simvastatin (Pint =0.034).

216 e the impact of simvastatin-ezetimibe versus simvastatin-placebo on cardiovascular-related hospitaliz

217 ith either 80 mg simvastatin (n=20) or 10 mg simvastatin plus 10 mg ezetimibe (n=19) for 6 weeks.

218 e incidence of ESRD (1057 [33.9%] cases with simvastatin plus ezetimibe versus 1084 [34.6%] cases wit

219 k was to assess efficacy and tolerability of simvastatin plus vitamin D for migraine prevention in ad

220 The results demonstrate that simvastatin plus vitamin D is effective for prevention o

221 Compared to placebo, participants using simvastatin plus vitamin D3 demonstrated a greater decre

222 Simvastatin potently stimulated leiomyoma cell apoptosis

223 Simvastatin protected the spleen from apoptosis, reduced

224 Thus, we hypothesized that simvastatin protects against burn-induced apoptosis in t

225 In static cellular experiments, 15-25 mum simvastatin reduced adhesion by K562 cells expressing re

226 Cdc42 were activated in senescent cells, and simvastatin reduced both activities.

227 In human myometrial cells, simvastatin reduced proinflammatory mediator mRNA and pr

228 e first and all recurrent strokes, ezetimibe/simvastatin reduced stroke of any etiology (HR, 0.83; 95

229 We show that simvastatin reduced the incidence of PTB in a validated

230 Only high-dose simvastatin reduced the relative proportion of sphingomy

231 Simvastatin reduces burn-induced splenic apoptosis via d

232 Thus, simvastatin reduces PTB incidence in mice, inhibits myom

233 Ezetimibe, when added to simvastatin, reduces cardiovascular events after acute c

234 omized to a placebo/simvastatin or ezetimibe/simvastatin regimen and followed for a median of 6 years

235 Independent risk factors for simvastatin-related myopathy and relevance to different

236 Simvastatin rescued neutrophil migration with age and du

237 Simvastatin resulted in a significant decrease in plasma

238 In 1 trial (n = 248), ezetimibe with simvastatin resulted in greater LDL-C reductions compare

239 (n = 550) were treated without (WS) or with simvastatin (S) at 20, 40 or 80 mg/day had HOMA2S on adm

240 (D6) day after MI in patients randomized to simvastatin (S)10 or 80 mg/day during hospitalization (n

241 loaded with the HMG-CoA reductase inhibitor simvastatin [S], were evaluated in the apolipoprotein E-

242 This property appears to assist in simvastatin's ability to suppress production of key MRSA

243 This suggests that simvastatin's beneficial effects in MS are independent o

244 the combination of angiopoietin-2 siRNA and simvastatin showed no additive benefit.

245 STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of

246 In contrast, rosuvastatin and simvastatin significantly reduced total and ABCA1-specif

247 RSA skin infection experiment confirmed that simvastatin significantly reduces the bacterial burden a

248 Lovastatin (LOV) and simvastatin (SIM) increased DeltaPsi in HepG2 and Huh7 h

249 This study evaluates the effect of a novel simvastatin (SIM) prodrug (capable of delivering high do

250 Simvastatin (SIM), a widely used anti-lipidemic drug, ha

251 tion and bone grafting with or without local simvastatin (SIM).

252 Together, our findings highlight that simvastatin substantially improves the overall health an

253 Furthermore, simvastatin suppressed BCa cell metastasis by inhibiting

254 psulation efficiencies of a hydrophobic drug simvastatin (SV) and a photosensitizer protoporphyrin IX

255 Simvastatin targets the metal ion-dependent adhesion sit

256 d animals were treated with atorvastatin and simvastatin, the two most prescribed statins.

257 Simvastatin therapy did not affect circulating levels of

258 A post hoc analysis demonstrated that simvastatin therapy was associated with improved hospita

259 Simvastatin therapy, although safe and associated with m

260 Ezetimibe, when added to simvastatin therapy, reduces cardiovascular events after

261 event, would also be reduced with ezetimibe/simvastatin therapy.

262 0.31-0.86; P=0.011) with ezetimibe added to simvastatin therapy.

263 n CV death/MI/iCVA at 7 years with ezetimibe/simvastatin, thus translating to a number-needed-to-trea

264 We assessed whether adding simvastatin to standard therapy could reduce rebleeding

265 n a randomized controlled trial, addition of simvastatin to standard therapy did not reduce rebleedin

266 The ability of simvastatin to target CR3 in its ligand binding-activate

267 vastatin group (9%) (hazard ratio for adding simvastatin to therapy = 0.39; 95% confidence interval:

268 ving noncardiac solid organ transplants from simvastatin-treated donors.

269 , the FAB score was 1.2 points higher in the simvastatin-treated group than in the placebo group (95%

270 protein cholesterol levels were lower in the simvastatin-treated patients than in those who received

271 mpared with the normolipidemic patients, the simvastatin-treated patients with hyperlipidemia showed

272 centrations were significantly higher in the simvastatin-treated patients with hyperlipidemia than in

273 Donor simvastatin treatment did not affect donor lipid levels

274 own-regulated in persons taking statins, and simvastatin treatment of C2C12 cells suppressed NEDD4 tr

275 Donor simvastatin treatment reduces biomarkers of myocardial i

276 Simvastatin treatment reduces CoQ synthesis and promotes

277 Results: Organ donor simvastatin treatment significantly reduced the heart re

278 Long-term simvastatin treatment vastly improved overall muscle hea

279 ls) were given intraperitoneal injections of simvastatin; tumor growth was monitored and tumors were

280 Discontinuation was higher in the placebo+simvastatin versus ezetimibe+simvastatin arm (KM rate 52

281 nternational Trial), which evaluated placebo+simvastatin versus ezetimibe+simvastatin in patients hos

282 duals with CKD was shown with ezetimibe plus simvastatin versus placebo.

283 randomized, double-blind trial of ezetimibe/simvastatin versus placebo/simvastatin (IMPROVE-IT [Impr

284 val [CI], 0.73-1.00; P=0.052) with ezetimibe/simvastatin versus placebo/simvastatin, driven by a sign

285 ividuals from the IMPROVE-IT (ezetimibe plus simvastatin versus simvastatin alone in individuals with

286 The use of ezetimibe/simvastatin versus simvastatin in IMPROVE-IT (Improved R

287 e significantly reduced by 9% with ezetimibe/simvastatin vs placebo/simvastatin (incidence-rate ratio

288 etemcomitans lipopolysaccharide (LPS), while simvastatin was given to some of the rats via gavage.

289 rhabdomyolysis in patients receiving 40 mg/d simvastatin was higher than expected.

290 9% of statin use); the defined daily dose of simvastatin was lower in cases than in controls (21-40 m

291 Simvastatin was most efficient and decreased P. gingival

292 s and outcomes for simvastatin and ezetimibe/simvastatin was prespecified in Improved Reduction of Ou

293 Simvastatin was the most commonly prescribed statin (acc

294 Simvastatin was well tolerated in this elderly and multi

295 dhering monocytes potentiated the effects of simvastatin where only a 50-100 nm concentration of the

296 chemic stroke with E/S compared with placebo/simvastatin, whereas patients without DM at low or moder

297 Simvastatin, which degrades the mutant form of p53, also

298 dyslipidemia trial compared fenofibrate plus simvastatin with placebo plus simvastatin.

299 ed to establish whether early treatment with simvastatin would decrease the time that survivors of cr

300 dy tested the hypothesis that treatment with simvastatin would improve clinical outcomes in patients